CN117017887A - Composition for relieving and reducing wrinkles and application thereof - Google Patents
Composition for relieving and reducing wrinkles and application thereof Download PDFInfo
- Publication number
- CN117017887A CN117017887A CN202310939814.0A CN202310939814A CN117017887A CN 117017887 A CN117017887 A CN 117017887A CN 202310939814 A CN202310939814 A CN 202310939814A CN 117017887 A CN117017887 A CN 117017887A
- Authority
- CN
- China
- Prior art keywords
- parts
- wrinkle
- extract
- mannose
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 76
- 230000001153 anti-wrinkle effect Effects 0.000 claims abstract description 71
- 102000008186 Collagen Human genes 0.000 claims abstract description 34
- 108010035532 Collagen Proteins 0.000 claims abstract description 34
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 34
- 229920001436 collagen Polymers 0.000 claims abstract description 34
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 25
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 25
- 239000011347 resin Substances 0.000 claims abstract description 25
- 229920005989 resin Polymers 0.000 claims abstract description 25
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 claims abstract description 23
- NDVRKEKNSBMTAX-MVNLRXSJSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O NDVRKEKNSBMTAX-MVNLRXSJSA-N 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 15
- 239000011734 sodium Substances 0.000 claims abstract description 15
- 241000545744 Hirudinea Species 0.000 claims abstract description 14
- 229940064064 purslane extract Drugs 0.000 claims abstract description 14
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 claims abstract description 11
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims description 46
- 239000003906 humectant Substances 0.000 claims description 42
- 239000003963 antioxidant agent Substances 0.000 claims description 36
- 230000003078 antioxidant effect Effects 0.000 claims description 36
- 239000002738 chelating agent Substances 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000003755 preservative agent Substances 0.000 claims description 28
- 230000002335 preservative effect Effects 0.000 claims description 28
- 239000002562 thickening agent Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 238000001816 cooling Methods 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 17
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 16
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical group CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 16
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 11
- 241000121220 Tricholoma matsutake Species 0.000 claims description 11
- 229940093497 ergothioneine Drugs 0.000 claims description 11
- 239000003009 skin protective agent Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 8
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 8
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical group CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 claims description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- 241000237903 Hirudo Species 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 8
- 229940101267 panthenol Drugs 0.000 claims description 8
- 235000020957 pantothenol Nutrition 0.000 claims description 8
- 239000011619 pantothenol Substances 0.000 claims description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 8
- 229960005323 phenoxyethanol Drugs 0.000 claims description 8
- 229920000058 polyacrylate Polymers 0.000 claims description 8
- -1 polyglycerol-10 Chemical compound 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 229940078465 vanillyl butyl ether Drugs 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000010041 presbyopia Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 206010052139 Eye oedema Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 241000219304 Portulacaceae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a relieving anti-wrinkle composition, which comprises the following components in parts by weight: 0.0289-0.1020 parts of mannose phosphate sodium, 0.0128-0.0450 parts of mannose, 0.1000-0.2500 parts of peach resin extract, 8.4686-19.9260 parts of purslane extract, 0.0500-0.1200 parts of recombinant III-type humanized collagen, 0.3500-1.0000 parts of hydroxypropyl tetrahydropyran triol and 0.0012-0.0060 parts of leech extract. According to the invention, mannose sodium phosphate, mannose and peach resin extract are selected to be matched with other components to realize synergistic effect, so that fine lines and wrinkles are improved, and the problem of dark circles after staying up night is solved; the composition is used for preparing the relieving anti-wrinkle eye mask, and the biological magnetic eye mask and the micro thermal induction circulation technology are utilized to promote the full absorption of effective active substances.
Description
Technical Field
The invention belongs to the field of cosmetics, and particularly relates to a composition for relieving and reducing wrinkles and application thereof.
Background
Currently, the eye mask on the market is in full view, and consumers cannot select the eye mask well. The eye skin is the thinnest, weakest and the easiest to age, so the requirement on the prescription is higher when the eye mask product is invented, not only the efficacy is reflected, but also the safety is considered. The eye skin is more sensitive than the skin at other parts, so that the eye product has high requirements on corrosion resistance and sanitary safety, and the problems of special eyes such as dark circles, eye bags, loose skin under eyes, fish tail lines and the like need to be developed, and the problems of the eye skin need to be improved.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides a composition which can improve the initial signs of visible skin aging, help improve the effects of fine lines and wrinkles, promote blood circulation around eyes, improve eye edema and solve the problem of dark circles after staying up night, and is applied to cosmetics.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the invention provides a composition for relieving and reducing wrinkle, which comprises the following components in parts by weight: 0.0289-0.1020 parts of mannose phosphate sodium, 0.0128-0.0450 parts of mannose, 0.1000-0.2500 parts of peach resin extract, 8.4686-19.9260 parts of purslane extract, 0.0500-0.1200 parts of recombinant III-type humanized collagen, 0.3500-1.0000 parts of hydroxypropyl tetrahydropyran triol and 0.0012-0.0060 parts of leech extract.
Sodium mannose phosphate, a metabolic product of the human body, participates in numerous metabolic pathways in the living body, including synthesis of amino acids, synthesis of fatty acids, gluconeogenesis, etc., and is produced during metabolism and provides energy to cells. Efficacy mechanism: the energy is directly supplied to the cells to restore the activity of mitochondria; autophagy key, enhancing cellular metabolism; to combat oxidative damage to cells; cell proliferation, collagen regeneration; the double effects of skin tightening and skin brightening are taken into account.
The recombinant III type humanized collagen is selected from recombinant humanized collagen, and the recombinant humanized collagen has better biological compatibility and has the advantages of good efficacy performance and low immunogenicity because the gene coding sequence or the amino acid sequence of the recombinant humanized collagen is consistent with the sequence of a human body in the technology; recombinant type III humanized collagen: by selecting the human III type collagen sequence with the length of 322 amino acids on the human 3 alpha 1 for expression, the homology with human collagen can be realized, which is equivalent to supplementing the collagen lost by human body, is more natural and safer, and achieves the real easy affinity and low sensitization.
The mannose and sodium mannose phosphate are combined with recombinant III type humanized collagen (CS 90) to metabolize the skin around the eyes and lighten the dark circles; the peach resin extract is combined with hydroxypropyl tetrahydropyran triol to tighten eye skin and eliminate eye bags, so that the anti-wrinkle effect is achieved. The anti-wrinkle and soothing cosmetic prepared by the anti-wrinkle composition has synergistic effect in anti-wrinkle and soothing skin by adding sodium mannose phosphate, mannose, peach resin extract, purslane extract, recombinant III type humanized collagen, hydroxypropyl tetrahydropyran triol and leech extract in a specific weight part range.
Preferably, the anti-wrinkle relieving composition comprises the following components in parts by weight: 0.0680 parts of mannose phosphate sodium, 0.0300 part of mannose, 0.2300 parts of peach resin extract, 14.9445 parts of purslane extract, 0.1000 part of recombinant III type humanized collagen, 0.8000 part of hydroxypropyl tetrahydropyrantriol and 0.0050 part of leech extract.
The prepared anti-wrinkle and relieving cosmetic has the best effects of improving fine lines and wrinkles, promoting blood circulation around eyes, improving eye edema and solving black eyes after staying up night by matching and using specific parts by weight of mannose sodium phosphate, mannose, peach resin extract, purslane extract, recombinant III type humanized collagen, hydroxypropyl tetrahydropyran triol and bdellose extract.
In a second aspect, the present invention provides a soothing anti-wrinkle cosmetic comprising the soothing anti-wrinkle composition described above; the weight percentage of the relieving and anti-wrinkle composition in the cosmetic is 9.01-21.45%.
Preferably, the soothing and anti-wrinkle cosmetic is an eye mask essence.
Preferably, the soothing anti-wrinkle cosmetic further comprises a skin protectant, a thermal sensitizer, a moisturizer, a thickener, a chelating agent, an antioxidant, a preservative, a solubilizer, and water.
Preferably, the skin protectant comprises at least one of a medicinal layer porus extract, a pine mushroom extract, ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises at least one of trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises at least one of polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises at least one of phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
Aiming at the problems of dark circles, eye fine lines and eye skin relaxation, the research and development of eye mask products are conducted in the aspects of relief and wrinkle resistance; the purslane extract and the medicinal layer porus extract are added to achieve the best relieving effect, mannose sodium phosphate, peach resin extract, ergothioneine pine mushroom extract, recombinant III-type human collagen (CS 90) and the like are added to promote collagen regeneration, and the ergothioneine pine mushroom extract is combined with the leech extract to repair the eye skin to lighten fine lines, improve the moist feeling of the eye skin, improve the initial signs of visible skin aging and help to improve the fine lines and wrinkles.
Preferably, the anti-wrinkle relieving cosmetic comprises the following components in parts by weight: 9.01 to 21.45 percent of anti-wrinkle relieving composition, 0.29 to 1.05 percent of skin protective agent, 0.0002 to 0.0030 percent of thermal sensing agent, 4.98 to 15.79 percent of humectant, 0.18 to 0.64 percent of thickening agent, 0.0117 to 0.1040 percent of chelating agent, 0.38 to 0.66 percent of antioxidant, 0.36 to 0.62 percent of preservative, 0.0013 to 0.0324 percent of solubilizer and the balance of water.
The weight percentage of the components of the anti-wrinkle relieving cosmetic is within the range, and the anti-wrinkle relieving cosmetic has the effects of reducing fine wrinkles, resisting wrinkles and relieving.
More preferably, the soothing anti-wrinkle cosmetic comprises the following components in parts by weight: 16.18% of a relieving anti-wrinkle composition, 0.71% of a skin protective agent, 0.0010% of a heat sensitive agent, 11.83% of a humectant, 0.43% of a thickening agent, 0.0430% of a chelating agent, 0.55% of an antioxidant, 0.51% of a preservative, 0.0055% of a solubilizer and the balance of water.
The components of the anti-wrinkle relieving cosmetic adopt a specific weight percentage, and have the optimal effects of reducing fine wrinkles, resisting wrinkles and relieving.
The third aspect of the present invention provides a method for preparing a soothing anti-wrinkle cosmetic, comprising the steps of:
(1) Mixing thickener, chelating agent 0.01-0.10%, humectant 3.8-12.4% and water 40-80%, heating to 82-85deg.C, stirring for dissolving, and maintaining for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 0.55-3.2% humectant, 0.3-0.8% antioxidant, adding 3-8% water for dissolving, and heating for 20-30 min to completely dissolve;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.35% -0.8% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
A fourth aspect of the present invention provides a soothing anti-wrinkle ophthalmic membrane comprising the above-mentioned soothing anti-wrinkle cosmetic.
The relieving anti-wrinkle eye mask combines a biological magnetic eye mask and a micro thermal induction circulation technology, and can promote the full absorption of effective active substances.
2. Mechanism analysis:
selecting a high content of plant extract (purslane) as a research and development product for relieving eye fatigue and dryness; the absorption of active ingredients is promoted by using a biological magnet and micro-heating technology, and mannose sodium phosphate are combined with recombinant III-type humanized collagen (CS 90) to enable skin around eyes to be metabolized, so that dark circles are reduced; the peach resin extract is combined with hydroxypropyl tetrahydropyran triol to tighten eye skin and eliminate eye bags so as to achieve the anti-wrinkle effect; the ergothioneine pine mushroom extract and the leech extract are combined to repair the eye skin, lighten fine wrinkles and improve the moist feeling of the eye skin.
Compared with the prior art, the invention has the following beneficial effects:
1. mannose-6-phosphate based on plant origin significantly smoothes the skin and provides a tightening effect, improves the visible initial signs of skin aging, helps to improve fine lines and wrinkles;
2. promoting blood circulation around eyes, reducing vascular permeability, and solving the problem of dark circles after staying up night;
3. the biological magnetic eye mask and micro heat sense circulation technology are utilized to promote the full absorption of effective active substances.
Drawings
FIG. 1 is an external view of the biological magnetic eye mask product of the invention.
Fig. 2 is the results of an ocular anti-presbyopia test of a subject using the example 3 relief anti-wrinkle eye mask.
Fig. 3 is the results of an ocular anti-presbyopia test of a subject using comparative example 1 relief anti-wrinkle eye mask.
Fig. 4 is the results of an ocular anti-presbyopia test of a subject using comparative example 2 relief anti-wrinkle eye mask.
Fig. 5 is a result of an eye relief test of a subject using the example 3 relief anti-wrinkle eye mask.
FIG. 6 is a graph of the change in corner of the eye wrinkle volume in a subject using example 3 relief anti-wrinkle eye mask; * P <0.05 and p <0.01, p <0.001.
FIG. 7 is a graph of the change in length of canthus wrinkles using the example 3 relief anti-wrinkle eye mask in a subject; * Represents p <0.001.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
Example 1
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: sodium mannose phosphate 0.0289 parts, mannose 0.0128 parts, peach resin extract 0.1000 parts, purslane extract 8.4686 parts, recombinant type III humanized collagen 0.0500 parts, hydroxypropyl tetrahydropyran triol 0.3500 parts, and leech extract 0.0012 parts.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 9.01% of a relieving anti-wrinkle composition, 0.29% of a skin protective agent, 0.0002% of a heat sensitive agent, 4.98% of a humectant, 0.18% of a thickening agent, 0.0117% of a chelating agent, 0.38% of an antioxidant, 0.36% of a preservative, 0.0013% of a solubilizer and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.01% chelating agent, 3.8% humectant and 80% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 0.55% humectant and 0.35% antioxidant, adding 3% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.35% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Example 2
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: sodium mannose phosphate 0.0510 parts, mannose 0.0225 parts, peach resin extract 0.1680 parts, purslane extract 11.9556 parts, recombinant type III humanized collagen 0.0750 parts, hydroxypropyl tetrahydropyran triol 0.6000 parts, and leech extract 0.0035 parts.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 12.88% of a relieving anti-wrinkle composition, 0.45% of a skin protective agent, 0.0008% of a heat sensitive agent, 8.35% of a humectant, 0.30% of a thickening agent, 0.0324% of a chelating agent, 0.44% of an antioxidant, 0.41% of a preservative, 0.0041% of a solubilizer, and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.03% chelating agent, 5.94% humectant and 70% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 1.08% humectant and 0.4% antioxidant, adding 4% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.4% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Example 3
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: 0.0680 parts of mannose phosphate sodium, 0.0300 part of mannose, 0.2300 parts of peach resin extract, 14.9445 parts of purslane extract, 0.1000 part of recombinant III type humanized collagen, 0.8000 part of hydroxypropyl tetrahydropyrantriol and 0.0050 part of leech extract.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 16.18% of a relieving anti-wrinkle composition, 0.71% of a skin protective agent, 0.0010% of a heat sensitive agent, 11.83% of a humectant, 0.43% of a thickening agent, 0.0430% of a chelating agent, 0.55% of an antioxidant, 0.51% of a preservative, 0.0055% of a solubilizer and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.04% chelating agent, 8.4% humectant and 60% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 1.61% humectant and 0.5% antioxidant, adding 6% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.5% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Example 4
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: 0.1020 parts of mannose phosphate sodium, 0.0450 part of mannose, 0.2500 part of peach resin extract, 19.9260 parts of purslane extract, 0.1200 part of recombinant III type humanized collagen, 1.0000 part of hydroxypropyl tetrahydropyrantriol and 0.0060 part of leech extract.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 21.45% of a relieving anti-wrinkle composition, 1.05% of a skin protective agent, 0.0030% of a thermal sensitizer, 15.79% of a humectant, 0.64% of a thickener, 0.1040% of a chelating agent, 0.66% of an antioxidant, 0.62% of a preservative, 0.0324% of a solubilizer and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.1% chelating agent, 11.4% humectant and 50% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 2.16% humectant and 0.6% antioxidant, adding 5% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.6% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Comparative example 1
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: 0.0612 parts of mannose phosphate sodium, 0.0270 part of mannose, 12.9519 parts of purslane extract, 0.0800 part of recombinant III-type humanized collagen, 0.8500 parts of hydroxypropyl tetrahydropyran triol and 0.0040 part of leech extract.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 13.97% of a relieving anti-wrinkle composition, 0.81% of a skin protective agent, 0.0020% of a heat sensitive agent, 9.19% of a humectant, 0.40% of a thickening agent, 0.0526% of a chelating agent, 0.49% of an antioxidant, 0.46% of a preservative, 0.0818% of a solubilizer and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.05% chelating agent, 6.6% humectant and 70% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 0.92% humectant and 0.45% antioxidant, adding 3% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, recombinant III type humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.45% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Comparative example 1 was free of peach resin extract.
Comparative example 2
A composition for relieving and reducing wrinkle comprises the following components in parts by weight: peach resin extract 0.3000 parts, purslane extract 24.9075 parts, recombinant III type humanized collagen 0.2000 parts, hydroxypropyl tetrahydropyran triol 1.5000 parts, leech extract 0.0080 parts.
A soothing and anti-wrinkle cosmetic comprises the following components in percentage by weight: 26.92% of a relieving anti-wrinkle composition, 1.33% of a skin protective agent, 0.0040% of a heat sensitive agent, 17.01% of a humectant, 0.84% of a thickening agent, 0.1250% of a chelating agent, 0.78% of an antioxidant, 0.82% of a preservative, 0.1530% of a solubilizing agent and the balance of water.
The cosmetic is eye mask essence.
The skin protectant comprises medicinal layer fungus extract, pine mushroom extract and ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
The preparation method of the relieving and anti-wrinkle cosmetic comprises the following steps:
(1) Mixing thickener, 0.12% chelating agent, 12.4% humectant and 40% water, heating to 82-85deg.C, stirring for dissolving uniformly, and maintaining the temperature for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding 3.2% humectant and 0.7% antioxidant, adding 8% water for dissolving, and heating for 20-30 min to dissolve completely;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.8% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
Comparative example 2 was free of sodium mannose phosphate and mannose.
The appearance and physical and chemical indexes of the relieving and anti-wrinkle cosmetics prepared in the above examples 1-4 and comparative examples 1-2 meet the following standards:
appearance: pale yellow to yellow liquid
pH value (1:10 aqueous solution) 5.5-7.0;
heat resistance (45+/-2 ℃) for 2 months, and room temperature is recovered without abnormality;
cold-resistant (-18±2 ℃). After 2 months, the room temperature is restored, and no abnormality exists;
cycle test (45 ℃, normal temperature, -18 ℃): 3 cycles, and is qualified.
Experimental method
First eye anti-presbyopia test
The experimental method comprises the following steps: 120 male and female volunteers (25-35 years old) were selected and divided into 20 persons/group, and six groups were tested for inventive examples 1-4 and comparative examples 1-2; the condition of fine wrinkles of the eyes of the volunteers was recorded by photographing, and the invention examples 1 to 4 and comparative examples 1 to 2 were applied to the eyes (once for fifteen minutes every 3 days) and the change of fine wrinkles of the skin of the eyes was observed by using 0d, 28d, 56d, and compared by photographing. Group 1 smears example 1, group 2 used example 2, group 3 used example 3, group 4 used example 4, group 5 used comparative example 1, group 6 used comparative example 2. Scoring between 0 and 10 points according to the use effect, wherein 9 to 10 points are good, 7 to 8 points are good, 5 to 6 points are general, 3 to 4 points are poor, 1 to 2 points are poor, average values are obtained, and the comparison results are shown in table 1:
TABLE 1
| Group of | Scoring of |
| Example 1 | 3 |
| Example 2 | 6.5 |
| Example 3 | 10 |
| Example 4 | 9 |
| Comparative example 1 | 5 |
| Comparative example 2 | 4 |
The results showed that, of the results of the use of the volunteers tested, example 3 scored the highest and the volunteers were most satisfied.
The result of photographing and recording the condition of the fine wrinkles of the eyes of a volunteer randomly selected from a third group is shown in fig. 2; the photographed recording results of the eye fine line condition observed by one volunteer randomly selected from the fifth and sixth groups are shown in fig. 3 and 4.
The results show that the example 3 volunteers have a real photograph before and after 28 and 56 days of use, which is seen to improve the initial signs of visible skin aging, helping to improve the efficacy of fine lines and wrinkles. Comparative example 1: the product is not added with peach resin extract, the effect of fine line fading is weaker, and the wrinkles at the corners of eyes are not obviously improved. Comparative example 2: mannose and sodium mannose phosphate are not added into the product, and after the product is used by volunteers, the visible dry streak around eyes is not improved, and the anti-wrinkle effect is general.
(II) eye relief test
120 male and female volunteers (18-45 years old) were selected and divided into 20 persons/group, and six groups were tested for inventive examples 1-4 and comparative examples 1-2; the condition of dark circles, puffiness of the eye and the like of the eyes of the volunteers were recorded by photographing, and the invention examples 1 to 4 and comparative examples 1 to 2 were applied to the eyes (once for fifteen minutes every 3 days) and the change of the skin fine lines of the eyes was observed by using 0d, 3d, 7d and 14d, and photographed for comparison. Group 1 smears example 1, group 2 used example 2, group 3 used example 3, group 4 used example 4, group 5 used comparative example 1, group 6 used comparative example 2. The score was between 0 and 10 points based on the effect, 9 to 10 points were good, 7 to 8 points were good, 5 to 6 points were generally poor, 3 to 4 points were poor, 1 to 2 points were poor, and the average was taken, and the results are shown in Table 2.
TABLE 2
| Group of | Scoring of |
| Example 1 | 4 |
| Example 2 | 7 |
| Example 3 | 10 |
| Example 4 | 9 |
| Comparative example 1 | 8 |
| Comparative example 2 | 7.5 |
One volunteer was randomly drawn in the third group to take a comparison of the photographs before and after the test, and the results are shown in fig. 5.
The results showed that volunteers were most satisfied with the results satisfaction score, example 3 product users; tests show that the invention has the functions of promoting blood circulation around eyes, improving eye edema and solving the problem of dark circles after staying up night.
(III) canthus wrinkle volume detection
Test sample: the soothing anti-wrinkle eye mask prepared in example 3.
The experimental method comprises the following steps:
1. the scheme is based on reference: a clinical evaluation method for improving canthus wrinkle effect of T/SHRH 018-2019 cosmetics.
2. Test instrument: the skin fast optical imaging system PRIMOS-CR.
3. The face was selected for subjects with visible canthus lines, canthus wrinkles, and ages ranging from 25 to 35 years. The eye skin photographs of the test sites of the subjects were tested before, after, and after 14 days, 28 days, and 56 days of continuous use of the product, respectively, using the front and rear control method. The evaluation results before and after the product is used are compared by a statistical test method so as to judge whether the statistical difference exists.
4. The test principle is a digital optical three-dimensional image analysis instrument developed on the basis of a digital microscopic fringe projector. Stripe light having a sinusoidal density at the time of testing is projected onto the skin or the surface of the object under test. The stripe light will be bent and deformed due to the uneven surface of the skin or the measured object, and the CCD camera placed at a specific angle will record the change at the same time. By testing the position change of the stripe light and the gray values of all image points, a digital three-dimensional image of the whole test skin surface or test object can be obtained. Different stripe lights can be selected for projection according to different testing tasks.
Test results: as shown in tables 3 and 4 and fig. 6.
TABLE 3 results of eye corner wrinkle volume detection
TABLE 4 rate of change in corner of eye wrinkle volume
Note that: the data in the table are mean ± standard error.
The subject continuously uses the relieving anti-wrinkle eye mask prepared in the example 3 for 14 days, the volume of the canthus wrinkles in the tested area is remarkably reduced (p is less than 0.001) compared with the basal value, and the reduction rate is 16.71%; subjects continuously used the relieving anti-wrinkle eye mask prepared in the example 3 for 28 days, the volume of the canthus wrinkles in the tested area is obviously reduced (p is less than 0.05) compared with the basal value, and the reduction rate is 9.24%; the subject continuously used the relieving and anti-wrinkle eye mask prepared in example 3 for 56 days, and the volume of the canthus wrinkles in the tested area is remarkably reduced (p is less than 0.01) compared with the basal value, and the reduction rate is 18.40%.
(IV) subject eye corner wrinkle Length statistics
Test sample: the soothing anti-wrinkle eye mask prepared in example 3.
The experimental method comprises the following steps: the scheme is based on reference: a clinical evaluation method for improving canthus wrinkle effect of T/SHRH 018-2019 cosmetics.
2. Test instrument: the skin fast optical imaging system PRIMOS-CR.
3. The face was selected for subjects with visible canthus lines, canthus wrinkles, and ages ranging from 25 to 35 years. The eye skin photographs of the test sites of the subjects were tested before, after, and after 14 days, 28 days, and 56 days of continuous use of the product, respectively, using the front and rear control method. The evaluation results before and after the product is used are compared by a statistical test method so as to judge whether the statistical difference exists.
4. The test principle is a digital optical three-dimensional image analysis instrument developed on the basis of a digital microscopic fringe projector. Stripe light having a sinusoidal density at the time of testing is projected onto the skin or the surface of the object under test. The stripe light will be bent and deformed due to the uneven surface of the skin or the measured object, and the CCD camera placed at a specific angle will record the change at the same time. By testing the position change of the stripe light and the gray values of all image points, a digital three-dimensional image of the whole test skin surface or test object can be obtained. Different stripe lights can be selected for projection according to different testing tasks.
Test results: as shown in tables 5 and 6 and fig. 7.
TABLE 5 results of eye corner wrinkle Length detection
TABLE 6 rate of change in eye corner wrinkle Length
Note that: the data in the table are mean ± standard error.
The subject continuously uses the relieving anti-wrinkle eye mask prepared in the example 3 for 14 days, 28 days and 56 days, the eye corner wrinkle length of the tested area is obviously reduced (p is less than 0.001) compared with the base value, and the reduction rates are respectively 20.35%, 20.03% and 18.93%.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The composition for relieving and reducing wrinkle is characterized by comprising the following components in parts by weight: 0.0289-0.1020 parts of mannose phosphate sodium, 0.0128-0.0450 parts of mannose, 0.1000-0.2500 parts of peach resin extract, 8.4686-19.9260 parts of purslane extract, 0.0500-0.1200 parts of recombinant III-type humanized collagen, 0.3500-1.0000 parts of hydroxypropyl tetrahydropyran triol and 0.0012-0.0060 parts of leech extract.
2. The soothing anti-wrinkle composition according to claim 1, comprising the following components in parts by weight: 0.0680 parts of mannose phosphate sodium, 0.0300 part of mannose, 0.2300 parts of peach resin extract, 14.9445 parts of purslane extract, 0.1000 part of recombinant III type humanized collagen, 0.8000 part of hydroxypropyl tetrahydropyrantriol and 0.0050 part of leech extract.
3. A soothing anti-wrinkle cosmetic comprising a soothing anti-wrinkle composition according to any one of claims 1 to 2; the weight percentage of the relieving and anti-wrinkle composition in the cosmetic is 9.01-21.45%.
4. The soothing anti-wrinkle cosmetic according to claim 3, wherein the cosmetic is an eye mask essence.
5. The soothing anti-wrinkle cosmetic according to claim 4, further comprising a skin protectant, a thermal sensitizer, a moisturizer, a thickener, a chelator, an antioxidant, a preservative, a solubilizer, and water.
6. The soothing anti-wrinkle cosmetic according to claim 5, wherein the skin protectant comprises at least one of a medicinal layer porus extract, a pine mushroom extract, ergothioneine; the thermal agent is vanillyl butyl ether; the humectant comprises at least one of trehalose, butanediol, polyglycerol-10, sodium hyaluronate, panthenol, 1, 2-hexanediol, ethylhexyl glycerol, 1, 2-pentanediol and glycerol; the thickener comprises at least one of polyacrylate crosslinked polymer-6 and xanthan gum; the chelating agent is disodium EDTA and the antioxidant is p-hydroxyacetophenone; the preservative comprises at least one of phenoxyethanol, octanol and octanoyl hydroxamic acid; the solubilizer is PEG-40 hydrogenated castor oil.
7. The soothing anti-wrinkle cosmetic according to any of claims 3 to 6, comprising the following components in percentage by weight: 9.01 to 21.45 percent of anti-wrinkle relieving composition, 0.29 to 1.05 percent of skin protective agent, 0.0002 to 0.0030 percent of thermal sensing agent, 4.98 to 15.79 percent of humectant, 0.18 to 0.64 percent of thickening agent, 0.0117 to 0.1040 percent of chelating agent, 0.38 to 0.66 percent of antioxidant, 0.36 to 0.62 percent of preservative, 0.0013 to 0.0324 percent of solubilizer and the balance of water.
8. The soothing anti-wrinkle cosmetic according to claim 7, comprising the following components in weight percent: 16.18% of a relieving anti-wrinkle composition, 0.71% of a skin protective agent, 0.0010% of a heat sensitive agent, 11.83% of a humectant, 0.43% of a thickening agent, 0.0430% of a chelating agent, 0.55% of an antioxidant, 0.51% of a preservative, 0.0055% of a solubilizer and the balance of water.
9. A method for preparing a soothing anti-wrinkle cosmetic as claimed in any of claims 3 to 8, comprising the steps of:
1) Mixing thickener, chelating agent 0.01-0.10%, humectant 3.8-12.4% and water 40-80%, heating to 82-85deg.C, stirring for dissolving, and maintaining for 15-20 min;
(2) Cooling to 65-75deg.C, sequentially adding mannose sodium phosphate, mannose, 0.55-3.2% humectant, 0.3-0.8% antioxidant, adding 3-8% water for dissolving, and heating for 20-30 min to completely dissolve;
(3) Stirring and cooling to 42-45deg.C, sequentially adding herba Portulacae extract, peach resin extract, recombinant III humanized collagen, hydroxypropyl tetrahydropyran triol, hirudo extract, skin protectant, 0.35% -0.8% antiseptic, and the rest humectant, antioxidant, chelating agent, solubilizer and water, homogenizing;
(4) Stirring and cooling to 38 ℃, adding the pre-dissolved solubilizer, the thermosensor and the residual preservative, and homogenizing to be completely uniform.
10. A soothing anti-wrinkle eye mask comprising a soothing anti-wrinkle cosmetic according to any one of claims 3 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310939814.0A CN117017887A (en) | 2023-07-28 | 2023-07-28 | Composition for relieving and reducing wrinkles and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310939814.0A CN117017887A (en) | 2023-07-28 | 2023-07-28 | Composition for relieving and reducing wrinkles and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117017887A true CN117017887A (en) | 2023-11-10 |
Family
ID=88630930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310939814.0A Pending CN117017887A (en) | 2023-07-28 | 2023-07-28 | Composition for relieving and reducing wrinkles and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117017887A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338627A (en) * | 2023-11-15 | 2024-01-05 | 广州品域美妆创新科技有限公司 | Anti-wrinkle tightening polypeptide composition and application thereof |
| CN117618280A (en) * | 2024-01-26 | 2024-03-01 | 苏州日月年世生物科技有限公司 | Collagen anti-aging composition and application thereof |
-
2023
- 2023-07-28 CN CN202310939814.0A patent/CN117017887A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338627A (en) * | 2023-11-15 | 2024-01-05 | 广州品域美妆创新科技有限公司 | Anti-wrinkle tightening polypeptide composition and application thereof |
| CN117618280A (en) * | 2024-01-26 | 2024-03-01 | 苏州日月年世生物科技有限公司 | Collagen anti-aging composition and application thereof |
| CN117618280B (en) * | 2024-01-26 | 2024-04-30 | 杭州译象生物科技有限公司 | Collagen anti-aging composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117017887A (en) | Composition for relieving and reducing wrinkles and application thereof | |
| CN105125476A (en) | Anti-wrinkle essence and preparing method thereof | |
| CN109394645B (en) | Smearing type water acupuncture essence and preparation method thereof | |
| CN111450010A (en) | Composition with anti-aging effect and application thereof in cosmetics | |
| CN103919704A (en) | Anti-aging essence | |
| CN111658565A (en) | Easily-absorbed anti-wrinkle tightening essence and preparation method thereof | |
| CN1713888B (en) | Cream for treatment of skin injured by the sun | |
| CN108836901A (en) | A kind of facial mask essence of the Product filtrate containing saccharomycetes to make fermentation and preparation method thereof | |
| CN110974736A (en) | Essence milk and production process thereof | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN108309817A (en) | A kind of whitening mask Essence and preparation method thereof using resveratrol | |
| CN111631981A (en) | Composition with anti-wrinkle effect, cosmetic and application of composition | |
| CN111568797A (en) | Composition for quickly removing fine lines and application thereof | |
| CN113633575A (en) | Skin color brightening composition and preparation method of essence thereof | |
| CN112545960A (en) | Bionic structure-based multifunctional repair sleep mask and preparation method thereof | |
| CN112006948A (en) | Moisturizing and anti-wrinkle eye cream containing ganoderma lucidum extract | |
| CN108451790B (en) | Moisturizing essence containing hydrophilic keratin and preparation method thereof | |
| JP2019202996A (en) | COSMETIC COMPOSITION COMPRISING γ-POLYGLUTAMIC ACID AS ACTIVE COMPONENT | |
| CN115919699A (en) | Acne-removing composition and application thereof in cosmetics | |
| CN109394632B (en) | Allergy-relieving moisturizing lotion and preparation method thereof | |
| CN115068361A (en) | Blue copper peptide double agent and use method and application thereof | |
| CN114288201A (en) | Composition for removing under-eye puffiness and fading black eye circles and preparation method and application thereof | |
| CN115006303A (en) | Anti-allergy moisturizing skin-activating essence lotion and preparation method thereof | |
| CN108888573B (en) | Soothing and moisturizing cream and preparation method thereof | |
| CN112220706A (en) | Anti-aging composition, cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |